SciVac Therapeutics agrees to acquire VBI Vaccines

Tools

Rehovot, Israel-based SciVac Therapeutics announced Monday its intention to acquire VBI Vaccines ($VBIV) to form a commercial-stage company with a licensed hepatitis B vaccine and a pipeline of preventative and therapeutic vaccine candidates. VBI will become a wholly owned subsidiary of SciVac, which will rename itself VBI Vaccines. More

Filed Under
SciVac Therapeutics,

Comments